<DOC>
	<DOCNO>NCT00005843</DOCNO>
	<brief_summary>Phase II trial study effectiveness R115777 treat patient metastatic pancreatic cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>R115777 Treating Patients Who Have Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety effectiveness R115777 patient metastatic pancreatic cancer . II . Determine response rate , time progression , 6 month survival rate patient treatment regimen . III . Assess pharmacokinetics treatment regimen patient population . OUTLINE : This multicenter study . Patients receive oral R115777 twice daily 21 consecutive day . Treatment continue every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas Measurable metastatic disease No prior treatment metastatic disease except immunotherapy ( e.g. , antibody , vaccine , cytokine ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 WBC least 4,000/mm3 OR granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Bilirubin great 2.0 mg/dL SGOT/SGPT great 2 time normal Creatinine great 2.0 mg/dL OR creatinine clearance least 50 mL/min Not pregnant nursing Fertile patient must use effective contraception 3 month study No concurrent illness active infection would preclude study No prior malignancy allow unless disease free time period consider appropriate cure specific cancer No history allergy imidazole compound ( e.g. , fluconazole , ketoconazole , miconazole , itraconazole , clotrimazole ) PRIOR CONCURRENT THERAPY : No prophylactic filgrastim ( GCSF ) , sargramostim ( GMCSF ) , thrombopoietin Primary neoadjuvant adjuvant chemotherapy allow least 6 month prior detection metastatic disease Primary radiotherapy allow least 6 month prior detection metastatic disease No concurrent use proton pump inhibitor ( e.g. , omeprazole )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>